Quanterix Priced, Nasdaq: QTRX

Makes next-generation protein detection tests for clinical research.

Industry: Health Care

Latest Trade: $17.75 0.00 (0.0%)

First Day Return: +16.5%

Return from IPO: +18.3%

Industry: Health Care

We are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Our platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. These capabilities provide our customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to better characterize the continuum between health and disease. We believe this greater insight provided by our platform, in research applications today and in diagnostic and precision health settings in the future, will enable the development of novel therapies and diagnostics and facilitate a paradigm shift in healthcare from an emphasis on treatment to a focus on earlier detection, monitoring, prognosis and, ultimately, prevention. In addition to enabling new applications and insights in protein analysis, we are also developing our Simoa technology to detect nucleic acids in biological samples.
more less
IPO News for Quanterix
more
IPO Data
IPO File Date 11/09/2017
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.3
Deal Size ($mm) $64
IPO Data
IPO Date 12/06/2017
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.3
Deal Size ($mm) $64
Underwriters
more
Company Data
Headquarters Lexington, MA
Founded 2007
Employees 122
Website www.quanterix.com